SOAT1 and breast carcinoma: Protein tyrosine phosphatase non-receptor type 2 (PTPN2), also known as T-cell PTP, is another tyrosine-specific PTP that may modulate ER+ breast cancer sensitivity to tamoxifen treatment by lowering the JAK-STAT cancerous signaling pathway [40].